BCAL Diagnostics (ASX:BDX) has announced the appointment of Anne Louise Arnett as Chief Executive Officer, effective 1 June 2026, as the company accelerates the commercial rollout of its early cancer detection products.
The Sydney-based diagnostics group said Ms Arnett brings more than 25 years of commercial and operational leadership across medical technology, with experience launching diagnostics and capital equipment into Australian and international markets.
Her arrival coincides with BCAL preparing to bring multiple new products to market, including expansions of its BREASTESTplus test and development of a multi-cancer early detection platform.
BCAL Executive Chair Jayne Shaw described Ms Arnett as a leader with the specific skillset needed to build commercial systems and scale organisations for growth.
The board also acknowledged outgoing CEO Shane Ryan, who will remain with BCAL as Director of Clinical Affairs, Breast Cancer, to ensure continuity of the company's core breast program during the leadership transition. Jayne Shaw will transition from Executive Chair to Non-Executive Chair, effective 1 July 2026, while remaining active on the board.
Ms Arnett has a track record of growing regional businesses and introducing diagnostic testing. Her recent roles include General Manager at Arthrex, where she built the Australian and New Zealand operations from a distributor model to direct-market sales, achieving strong growth, and Vice President and General Manager at Hologic, where she led portfolios across diagnostic imaging, women's health surgery, and diagnostics. Earlier roles at Stryker included global marketing and new product launches across international markets.
The company noted its exclusive licensing arrangements with ClearNote Health for several Avantect tests in Australia and New Zealand and reiterated its focus on improving screening and diagnostic outcomes for breast health through non-invasive blood testing used alongside mammography.